The study, the largest OIT investigation to date, focused on 496 participants between the ages of 4 and 17, all of whom were highly allergic to peanuts.
As anyone reading the ingredients of everyday items such as chocolate bars or savoury sauces will tell you, having a peanut allergy requires an terrible lot of care when eating something unfamiliar.
The experimental treatment, called AR101 for the time being, is not a one-and-done cure for peanut allergies, but rather a daily regimen of purified peanut protein-filled capsules that reduces the body's reaction to peanut protein through sustained exposure.
However, according to Christina Ciaccio, Associate Professor from the University of Chicago in the USA, the drug "is not a quick fix, and it doesn't mean people with peanut allergy will be able to eat peanuts whenever they want".
67% of patients receiving AR101, an orally administered peanut-derived biologic, tolerated a single dose of at least two peanuts (500 - 600 mg of peanut protein) while 85% who completed the study tolerated this amount.
Currently, there are there are currently no approved treatments for those patients suffering from peanut allergies.
Forecasters warn Thanksgiving could be the coldest on record
In the valley the main impacts will be rain and wind with a rain/snow mix at about 5,500 feet Wednesday night. The majority of the snow will fall in the high Sierra but roads will be impacted at pass level as well.
E. Coli Outbreak in Ontario, Quebec Linked to Romaine Lettuce
Health officials say two people in New Hampshire have been affected by a new E. coli outbreak linked to romaine lettuce . That outbreak, which was declared over in June, was traced to contamination in the Yuma, Ariz., growing region.
Elon Musk Smoking Weed Sparks NASA Review Into SpaceX
It would be the first time astronauts were launched from a spacecraft on American soil since the end of the space shuttle program. ASAP members also pushed back against claims that the problems were merely "paperwork" issues delaying the test flights.
With AR101, rather than simply using peanut flour, patients take a carefully produced and measured dose of powder that has a specific amount of different proteins in it. After nine to 12 months of treatment, the study showed that two-thirds of those who took the peanut allergy drug were able to tolerate two peanuts a day.
After one year of treatment with a newly invented drug by Immune Therapeutics, says about 70% of children and teenagers suffering from peanut allergies were able to accept two peanuts or equivalent.
"Families live in fear of accidental exposure as allergic reactions can be very severe, and can even lead to death". "This has been around in the diet community for a while", she says, noting that it's marketed under the name PB2.
'The impact on our family life was huge'.
Now, one of the most common food allergies in the world could one day be reversed in many, thanks to a discovery involving a team from the Irish Centre for Foetal and Neonatal Translational Research (INFANT) based at University College Cork.
Researchers in 10 countries across North America and Europe conducted the trial, known as the Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization trial, or PALISADE, for short.